Endocrine Abstracts

Background: Patients with adrenal insufficiency (AI) exhibit increased morbidity, mortality and impaired quality of life (QoL) and conventional hydrocortisone replacement does not mimic the endogenous circadian pattern and may compromise adherence. A modified – release hydrocortisone formulation (Plenadren) for once-daily use is licensed in order to meet these needs.Objective: To audit the effects of treatment change from HC to Plenadren in an out-p...

Introduction: Subarachnoid haemorrhage (SAH) is associated with a mortality rate of 30% and the survivors face significant morbidity including fatigue, isolation, depression and sleep disorders; factors affecting general health related quality of life (QoL). QoL is also known to be decreased in pituitary-hypothalamic insufficiency and tends to improve after treatment. SAH has been suggested to be a common cause of hypopituitarism by some whereas not by others. We aimed to inve...

Background: Current NICE guidance states that insulin pump therapy (CSII) can be considered in Type 1 diabetes (T1DM) patients who suffer disabling hypoglycaemia in an attempt to reach glycaemic control or whose HbA1C remains high (>69 mmol/l) despite careful management on multiple daily injections (MDI).Aims: Our aims were to determine impact of CSII therapy on glycaemic control, BMI, incidence of severe hypoglycaemia and episodes of diabetic ketoac...

Lowered testosterone levels may be observed in up to 50% of ageing men with type 2 diabetes (T2D). Testosterone replacement therapy (TRT) increases lean body mass in men with lowered testosterone levels and T2D, but the effect of TRT on glucose metabolism has not been evaluated by euglycemic hyperinsulinemic clamp.We used gold standard methods to evaluate the effect of TRT on body composition, insulin sensitivity, and oxidative metabolism in men with T2D...

The current conventional glucocorticoid (GC) replacement therapy in primary adrenal insufficiency (Addison’s disease) and congenital adrenal hyperplasia (CAH) renders the cortisol levels unphysiological, resulting in very high levels alternating with almost undetectable levels of cortisol over the day. This reduces not merely the patient’s quality of life but increases the patient’s morbidity and mortality. The HPA axis is characterised by a dynamic circadian va...

Objective: In acromegaly, high GH/IGF1 levels are associated with abnormal glucose metabolism. Treatment with somatostatin analogues (SSAs) reduces the GH and IFG-1 levels. However, SSAs may worsen glucose homeostasis despite this, due to concomitant inhibition of insulin secretion. We studied the possible association between biochemical cure and glucose homeostasis in de novo patients with acromegaly.Design: Post hoc analysis from a ra...

Background: Central obesity in polycystic ovary syndrome (PCOS) is associated with increased inflammatory markers and increased risk for type 2 diabetes.Aim: To evaluate the long-term effects of metformin (M) and/or oral contraceptives (OC) on fat mass.Research design: Randomized, controlled study.Setting: Outpatient clinic.Methods: 90 patients with PCOS were randomized to 12 months M (...

Background: Polycystic ovary syndrome (PCOS) is associated with obesity and increased risk of type 2 diabetes mellitus.Aim: The aim of the present prospective cohort study was to investigate possible associations between PCOS and obstetric outcomes in 199 Danish women with PCOS and 995 controls and to describe the impact of different PCOS phenotypes on the risk of adverse obstetric outcomes.Methods: Women diagnosed with PCOS at Ode...

Introduction: Acromegaly is a rare disease caused by GH hypersecretion from a pituitary adenoma. However, accurate estimates of incidence and prevalence are scarce and not based on nationwide populations. It is well known that surgical cure may normalize mortality and improve morbidity but similar data are not available for patients receiving medical treatment.Method: We first validated the ICD-8 and ICD-10 diagnosis codes for acromegaly in The National ...

Objective: Early postoperative results for the Preoperative Octreotide Treatment of Acromegaly (POTA) study has been published, and like later randomized studies we demonstrated a beneficial effect of presurgical treatment with somatostatin analogues (SSA) in GH-secreting macroadenomas when evaluated 3–4 months postoperatively. However, concerns about a potential lingering effect of SSA and thereby potential false positive results have been raised. The objective of this s...